Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
97.78
-0.63 (-0.64%)
At close: May 9, 2025, 4:00 PM
97.68
-0.10 (-0.10%)
After-hours: May 9, 2025, 7:35 PM EDT
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $897.84M in the quarter ending March 31, 2025, a decrease of -0.46%. This brings the company's revenue in the last twelve months to $4.06B, up 5.76% year-over-year. In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth.
Revenue (ttm)
$4.06B
Revenue Growth
+5.76%
P/S Ratio
1.48
Revenue / Employee
$1,451,717
Employees
2,800
Market Cap
6.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
JAZZ News
- 4 days ago - Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance - PRNewsWire
- 10 days ago - Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - PRNewsWire
- 15 days ago - Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - PRNewsWire
- 17 days ago - Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma - PRNewsWire
- 18 days ago - Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 - PRNewsWire
- 19 days ago - Jazz Pharmaceuticals Completes Acquisition of Chimerix - PRNewsWire
- 4 weeks ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha